7,500 Shares in United Therapeutics Corporation $UTHR Bought by Suvretta Capital Management LLC

Suvretta Capital Management LLC purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,500 shares of the biotechnology company’s stock, valued at approximately $3,144,000.

Other hedge funds also recently added to or reduced their stakes in the company. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics in the third quarter valued at about $44,000. Finally, Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. HC Wainwright raised their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Finally, Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $548.09.

Insider Activity at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,000 shares of United Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the sale, the director directly owned 8,480 shares in the company, valued at $4,150,281.60. The trade was a 19.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ray Kurzweil sold 4,910 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.02, for a total transaction of $2,401,088.20. Following the completion of the sale, the director directly owned 12,670 shares of the company’s stock, valued at $6,195,883.40. The trade was a 27.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 338,947 shares of company stock valued at $165,516,573. Company insiders own 10.30% of the company’s stock.

United Therapeutics Trading Up 0.6%

Shares of United Therapeutics stock opened at $536.12 on Friday. The stock has a market capitalization of $23.50 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $548.12. The business’s 50 day simple moving average is $486.67 and its 200-day simple moving average is $460.13.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.19 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.